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Heparin-binding epidermal growth factor (HB-EGF), a mem-
ber of the epidermal growth factor (EGF) family, is implicated
in a variety of biological processes, including reproduction.
Previous studies describe increased levels of HB-EGF in the
human endometrium during the midsecretory stage of the
menstrual cycle, suggesting a function for HB-EGF in implan-
tation of the human blastocyst. Here we have investigated the
expression and function of the soluble and transmembrane
forms of HB-EGF in the human endometrium. We show that
the expression of the transmembrane form of HB-EGF in the
human endometrium is modulated according to the stage of
the menstrual cycle. We present data demonstrating that both
the soluble and transmembrane forms of HB-EGF induce DNA
synthesis in human endometrial stromal cells. Furthermore,
TNF has a cooperative effect on HB-EGF, EGF, TGF, and
betacellulin-induced DNA synthesis in stromal cells, suggest-
ing roles for the EGF family and TNF in regeneration and
maturation of human endometrium. Induction of DNA syn-
thesis by HB-EGF and its modulation by TNF in endometrial
stromal cells are mediated by the EGF receptor and not the
HB-EGF receptor ErbB4. Our data suggest key functions for
HB-EGF, TNF, and the EGF receptor in endometrial matu-
ration, via autocrine/paracrine and juxtacrine pathways, in
preparation for embryo implantation. (J Clin Endocrinol
Metab 87: 0000–0000, 2002)
HEPARIN-BINDING epidermal growth factor (HB-EGF) is a member of the epidermal growth factor
(EGF) family and has been implicated in a variety of bio-
logical processes, such as wound healing, tumor growth,
smooth muscle cell hyperplasia, angiogenesis, and repro-
duction (1–3). It is synthesized by many cell types (4–8) as
a 208-amino acid transmembrane precursor (tm-HB-EGF)
containing EGF, heparin-binding, transmembrane, and cy-
toplasmic domains. The extracellular domain can be released
as a 12- to 22-kDa soluble form of HB-EGF (sol-HB-EGF),
probably as a result of the action of metalloproteinases (9–
11), although a substantial amount of transmembrane pre-
cursor can remain uncleaved on the cell surface (12). Both
tm-HB-EGF and sol-HB-EGF are biologically active (12). The
biological functions of both sol- and tm-HB-EGF are medi-
ated by the EGF receptor (EGFR; HER1) and ErbB4 (HER4)
(1, 13, 14). Activation of these types of receptors is believed
to occur as a consequence of ligand-induced receptor homo-
or heterodimerization (14).
The spatio-temporal expression of HB-EGF in rodents sug-
gests a function in uterine receptivity, embryonic well-being,
and implantation of the blastocyst (15, 16). In functional
studies, cells expressing tm-HB-EGF adhered to mouse blas-
tocysts (17), and sol-HB-EGF was found to stimulate prolif-
eration, hatching, outgrowth of trophoblast, and tyrosine
phosphorylation of EGFR in mouse blastocysts (16). It has
also been suggested that HB-EGF binds to ErbB4 expressed
on the trophectoderm of mouse blastocysts (18). Studies in
the baboon revealed that HB-EGF protein accumulation in-
creases in the endometrium on d 5 and 10 postovulation (19).
These data from animal studies are consistent with reports
addressing the human endometrium, in which HB-EGF
mRNA is detected throughout the menstrual cycle and its
levels increased before the implantation window (d 19–21 of
the menstrual cycle) (8, 20, 21). Furthermore, the expression
of both receptors for HB-EGF, EGFR and ErbB4, in the human
endometrium also undergoes cyclic changes (22–24). It has
also been suggested that HB-EGF has a function for sol-HB-
EGF in promoting the development of in vitro fertilized hu-
man embryos to the blastocyst stage and subsequent hatch-
ing (25).
The endometrial stroma undergoes extensive expansion in
preparation for embryo implantation, which is subsequently
shed during the menstrual stage of the cycle if the embryo
fails to implant. Several reports suggest that TNF has a
major role in regulation of the onset of menstruation. Ex-
pression of TNF mRNA has been reported to increase dur-
ing the secretory stage of the cycle (26, 27). Also, endometrial
biopsies obtained from the menstrual stage of the cycle have
been found to secrete higher levels of soluble TNF than
biopsies taken at any other stage (28). In addition, TNF has
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been reported to inhibit proliferation and to induce apoptosis
in endometrial epithelial cells (29). However, little is known
about possible functions in the endometrial stroma.
Here we have investigated the potential function of HB-
EGF and other EGFR ligands EGF, TGF, betacellulin (BTC),
and TNF, in the regeneration of the human endometrial
stroma. We describe the localization of the membrane-
anchored, as opposed to the soluble, form of HB-EGF,
present evidence for the modulation of DNA synthesis in
endometrial stromal cells by sol-HB-EGF and tm-HB-EGF,
and demonstrate that TNF cooperates with HB-EGF, EGF,




Tissue samples were collected in accordance with the requirements
of the Central Oxford research ethics committee. Endometrial samples
were obtained from patients, aged 20–49 yr, undergoing hysterectomy
for benign indications, who had regular 26- to 33-d menstrual cycles, and
who had received no hormonal medication in the preceding 3 months.
The cycle stage of the endometrium was assessed according to Noyes
criteria (30).
Tissue staining
Endometrial tissue samples were obtained from 12 women (7 tissues
from the proliferative and 5 from the secretory stages of menstrual
cycle). Sections (7 m) from paraffin-embedded tissue samples were
prepared as described previously (31). Tissue sections were incubated
in 10 g/ml goat antihuman HB-EGF antibodies (recognizing the in-
tracellular domain of the HB-EGF-precursor, detecting tm-HB-EGF;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 h at room tem-
perature. Control staining was performed with the same antibodies
preincubated with the corresponding antigenic peptides. Sections were
washed in three changes of PBS, then incubated in horseradish perox-
idase (HRP)-conjugated antigoat IgG for 1 h at room temperature and
washed as described above. Bound antibodies were detected with HRP
substrate diaminobenzidine tetrachloride (Sigma, Poole, UK).
Isolation and immunohistochemical staining of human
endometrial stromal cells
Endometrial tissues were processed for stromal cell culture as de-
scribed previously (32). The purity of the isolated cells was assessed by
staining with Thy-1 and vimentin, and in this study cells were either
used at consecutive passages between passages 1–6 or thawed from
early passage cultures. The percentages of Thy-1- and vimentin-positive
cells were approximately 84% and 92%, respectively, and remained
consistent with passage. Cultures of endometrial stromal cells seeded
onto coverslips were stained by the use of immunofluorescent tech-
niques as described previously (33). Specific antigens were detected by
incubation in 4 g/ml goat anti-HB-EGF (Santa Cruz Biotechnology,
Inc.), 15 g/ml anti-ErbB4 (clone HFR1) (34), or 5 g/ml mouse anti-
EGFR (BD PharMingen, San Diego, CA), followed by 15 g/ml of either
rabbit antigoat fluorescein isothiocyanate (FITC)-conjugated IgG
(Sigma) or donkey antimouse Texas Red-conjugated IgG (Jackson Im-
muoResearch Laboratories, Inc., West Grove, PA) antibodies. Goat and
mouse IgG were used in negative controls as appropriate. Coverslips
were mounted in Vectashield medium with DAPI (Vector Laboratories,
Inc., Burlingame, CA). The staining was observed using a Leitz DMRBE
microscope (Leica Corp., Wetzlar, Germany) and Openlab imaging soft-
ware (Improvision, UK).
Generation of CHO/HB-EGF cells and
membrane preparations
CHO cells expressing tm-HB-EGF were generated by transfection
with a cDNA encoding the full-length HB-EGF precursor cloned into
pEE14 (CHO/HB-EGF) using standard calcium phosphate precipitation
procedures. The control cell line (CHO/vector) was transfected with
pEE14. One-step amplification with 25 m methionine sulfoximine
(Sigma) was performed as described previously (35). Expression of
tm-HB-EGF was assessed by Western blot analysis of crude membrane
preparations derived from CHO/HB-EGF and CHO/vector. For this
purpose, confluent CHO cells in 75-cm2 flasks were washed with PBS,
scraped, and resuspended in 5 ml homogenization buffer [25 mm Tris-
7.5, 0.25 m sucrose, 1 mm EDTA, 1 mm dithiothreitol, 2 mm phenyl-
methylsulfonylfluoride (PMSF), 10 mg/ml leupeptin, and 1 mg/ml pep-
statin] and passed through a glass cell homogenizer. The cell
homogenate was centrifuged at 5,000  g for 10 min, followed by
centrifugation at 100,000  g for 2 h. The pellet was washed with
homogenization buffer and resuspended in RIPA (1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate in PBS)
supplemented with 2 mm PMSF, 10 mg/ml leupeptin, and 1 mg/ml
pepstatin. Proteins were separated by 12% SDS-PAGE and transferred
to a polyvinylidene difluoride membrane (Roche, Mannheim, Ger-
many). Western blotting was performed with 2 g/ml goat antihuman
HB-EGF (Santa Cruz Biotechnology, Inc.), followed by 60 ng/ml rabbit
antigoat IgG, and bound antibodies were detected with the use of the
Super Signal West Pico Chemiluminescent Substrate (Pierce Chemical
Co., Rockford, IL) according to the manufacturer’s instructions.
Cell preparations for testing the juxtacrine activity of tm-HB-EGF
were prepared from CHO/HB-EGF or CHO/vector cells plated into
9-cm petri dishes in Glasgow MEM (First Link Ltd., UK) containing 10%
dialyzed fetal calf serum (FCS), penicillin, streptomycin, and 25 m
methionine sulfoximine (Sigma). Confluent cultures were washed twice
in 2 mm NaCl in PBS and fixed with 3% paraformaldehyde in PBS for
5 min. The fixed cells were washed twice in DMEM containing 10% FCS,
scraped from the plate, and resuspended in serum-free DMEM. Fixed
cells (105) were added to each monolayer of stromal cells in 96-well
plates (plated at 104 cells/well) that had been previously serum-starved
for 18 h. The cocultures were incubated in serum-free medium for 24 h,
and thymidine incorporation assays were performed as described
below.
DNA synthesis assays
Stromal cells were seeded into 96-well plates (104 cells/well) in
DMEM supplemented with 10% FCS, 100 IU/ml penicillin, and 100
g/ml streptomycin. After 24 h the medium was changed to serum-free
DMEM, and the cells were incubated for a further 18 h. Cells were then
stimulated with combinations of recombinant HB-EGF, EGF, TGF,
BTC, and TNF (all from R&D Systems, Inc., Abingdon, UK), and
PD153035, a specific inhibitor of the tyrosine kinase activity of EGFR
(Calbiochem, La Jolla, CA), in serum-free DMEM for 24 h. Juxtacrine
activity was measured using a modification of a method described
previously (36). Fixed CHO/HB-EGF or CHO/vector cell membrane
preparations, prepared as described above, were added to each mono-
layer of stromal cells in 96-well plates (plated at 104 cells/well) and
serum-starved as described above. [3H]Thymidine (1 Ci; Amersham
Pharmacia Biotech, Little Chalfont, UK) was added to each well for the
last 4 h of incubation. Cells were washed three times in PBS and har-
vested, and the amount of incorporated [3H]thymidine was determined
using a -plate counter (Wallac, Inc., Turku, Finland).
Immunoprecipitation and Western blotting
Confluent stromal cell cultures in 9-cm petri dishes were starved in
serum-free medium for 18 h and then stimulated with 10 ng/ml HB-EGF
or overlaid with fixed CHO/HB-EGF (as described above) in serum-free
DMEM for 3 min at 37 C. Petri dishes were placed on ice and washed
twice with ice-cold PBS supplemented with 2 mm orthovanadate. Cells
were lysed for 10 min in RIPA supplemented with 2 mm orthovanadate,
2 mm sodium fluoride, 2 mm sodium pyrophosphate, 2 mm PMSF, 10
g/ml leupeptin, and 1 g/ml pepstatin in PBS. The cell lysates were
clarified by microcentrifugation at 5000  g for 15 min at 4 C. Immu-
noprecipitation was performed with 5 g of either anti-EGFR mouse
monoclonal (BD PharMingen) or anti-ErbB4 rabbit polyclonal (Santa
Cruz Biotechnology, Inc.) antibodies for 4 h at 4 C. The immune com-
plexes were collected by binding to protein A/G-Sepharose (Santa Cruz
Biotechnology, Inc.) using standard protocols. Proteins were separated
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by 7.5% SDS-PAGE and transferred onto a polyvinylidene difluoride
membrane (Roche). Phosphotyrosines were detected by incubation in 1
g/ml antibody clone 4G10 (Upstate Biotechnology, Inc., Lake Placid,
NY). EGFR and ErbB4 were detected in parallel blots incubated with 2
g/ml rabbit anti-EGFR (Santa Cruz Biotechnology, Inc.) or rabbit anti-
ErbB4 (Santa Cruz Biotechnology, Inc.). Bound antibodies were detected
by incubation in either 50 ng/ml sheep antimouse IgG (Amersham
Pharmacia Biotech) or 250 ng/ml rabbit antigoat IgG (DAKO Corp.,
Copenhagen, Denmark), both conjugated with HRP, with the use of the
methods described above.
Flow cytometry
Cultures of stromal cells were trypsinized, fixed in 0.25% parafor-
maldehyde and 2% glucose in PBS for 10 min at 4 C, and permeabilized
with 0.1% saponin and 0.1% BSA in PBS for 20 min at 4 C. Labeling was
performed with 5 g/ml of either mouse anti-EGFR monoclonal anti-
bodies (BD PharMingen, San Diego, CA) or mouse IgG (Sigma) in 2%
glucose and 5% normal human serum in PBS for 30 min at 4 C. Cells were
washed in 2% glucose and 0.1% BSA in PBS and incubated with 15
g/ml goat antimouse FITC-conjugated antibodies (Sigma) for 30 min
on ice. The cells were washed in 2% glucose and 5% normal human
serum in PBS and resuspended in PBS containing 2% FCS and 0.1%
NaN3. Samples were analyzed on a Coulter EPICS Elite flow cytometer
that was calibrated before each experiment with Flow Set Beads (Beck-
man Coulter, Inc., UK). FITC fluorescence was detected at 525 nm. Ten
thousand events were collected, and the results were expressed as the
mean channel brightness.
Statistical analysis
Data were analyzed using ANOVA (StatView 5.01 software, SAS
Institute, Inc., Cary, NC), and P  0.05 indicated significant differences
between datasets.
Results
Expression of tm-HB-EGF in the human endometrium is
modulated during the menstrual cycle
Previous data from this and other laboratories have re-
ported expression of HB-EGF mRNA and sol-HB-EGF pro-
tein in the endometrium (8, 21). Here we have analyzed in
detail the expression of the tm-HB-EGF-precursor (hereafter
referred to as tm-HB-EGF) in the human endometrium. Tis-
sue sections derived from different stages of the cycle were
stained with antibodies recognizing the C-terminal end of
tm-HB-EGF (Fig. 1). Proliferative stage endometrial tissues
exhibited staining for HB-EGF in both stroma and glandular
epithelium. Staining was most intense in the basalis, de-
creasing in intensity through the functionalis, and was not
detectable in the area adjacent to the lumenal part of the
endometrium (Fig. 1, A and C). Staining for tm-HB-EGF in
early to midsecretory stage tissues was intense throughout
the stroma and epithelium of both the basalis and functio-
nalis layers of the endometrium (Fig. 1B). High magnification
of secretory stage tissues revealed intense, membrane-asso-
ciated staining for tm-HB-EGF (Fig. 1C). There was a punc-
tate pattern of staining around the basal and apical surfaces
of glandular epithelium and some stromal cells. Staining
with anti-HB-EGF preincubated with control peptide
showed no reactivity with tm-HB-EGF (Fig. 1D).
tm-HB-EGF, EGFR, and ErbB4 are expressed in cultures of
endometrial stromal cells
The HB-EGF receptors EGFR and ErbB4 previously have
been shown to be expressed in human endometrial tissues
(23, 34). As the functions of sol- and tm-HB-EGF were to be
determined in cultures of endometrial stromal cells, the ex-
pression of EGFR, ErbB4, and tm-HB-EGF by these cells in
culture was assessed (Fig. 2). Stromal cells stained positively
with antibodies to the HB-EGF precursor, displaying a punc-
tate pattern of staining for tm-HB-EGF (Fig. 2A). Control
cultures treated with goat IgG were negative (Fig. 2B). The
receptors EGFR (Fig. 2C) and ErbB4 (Fig. 2D) were detected
in stromal cells, and both exhibited a punctate pattern of
staining. Although the punctate tm-HB-EGF staining was
reminiscent of that seen in vivo, the significance of this pat-
FIG. 1. Expression of tm-HB-EGF in
the human endometrium. Tissue sec-
tions derived from proliferative (A and
C) and secretory (B) endometrium were
stained with anti tm-HB-EGF antibod-
ies. Control staining was performed
with antibodies preincubated with the
appropriate control peptide (D). The re-
gion adjacent to the lumenal surface is
marked by an arrow. Scale bars, 50 m
(in A–C) and 125 m (D).
balt1/eg-jcem/eg-jcem/eg1202/eg9038-02a harringt S7 10/5/02 8:45 4/Color Figure(s): 1,2 Art: 1026142 Input-dt




tern of staining for the ligand and the receptors is not clear.
Control cultures treated with mouse IgG were negative
(Fig. 2E).
sol- and tm-HB-EGF promote DNA synthesis in
endometrial stromal cells
The effects of sol- and tm-HB-EGF on DNA synthesis in
human endometrial stromal cells were analyzed (Fig. 3) First
we assessed the response to HB-EGF of stromal cells at pas-
sages 1–6 in serum-free medium (Fig. 3A). Our analyses
confirmed that the cells retain the capacity to respond to
HB-EGF to a similar extent at the passages we used in this
study, and there was no significant difference in HB-EGF
responsiveness between passages.
In serum-free medium, sol-HB-EGF induced up to a 2-fold
increase in DNA synthesis compared with cells cultured in
the absence of sol-HB-EGF. However, in the presence of 5%
charcoal-stripped serum, stromal cells responded to sol-HB-
EGF with a 3- to 5-fold increase in DNA synthesis compared
with untreated controls (Fig. 3B), indicating that additional
factors in serum may act cooperatively with HB-EGF in pro-
moting DNA synthesis.
To analyze the juxtacrine activity of HB-EGF we generated
CHO expressing the tm-HB-EGF, CHO/HB-EGF, and a con-
trol cell line transfected with the vector, CHO/vector. In
crude membrane preparations from CHO/HB-EGF cells
TM-HB-EGF was detected as several species ranging from
15–35 kDa (Fig. 3C), correlating with the previously reported
pattern of protein species (37). Juxtacrine activity of HB-EGF
was tested by coincubating CHO/HB-EGF and CHO/vector
cells with stromal cells (Fig. 3D). In serum-free medium the
CHO/HB-EGF preparation induced a 2-fold increase in
[3H]thymidine incorporation compared with the CHO/vec-
tor. Cell preparations from CHO/vector also induced DNA
FIG. 2. Cultured endometrial stromal cells express both HB-EGF
receptors, EGFR and ErbB4, and tm-HB-EGF. Stromal cells were
grown on coverslips and stained for tm-HB-EGF (A), EGFR (C), and
ErbB4 (D). Control staining was performed with either goat or mouse
IgG (B and E, respectively). Scale bars, 10 m.
FIG. 3. Sol- and HB-EGF-precursor stim-
ulate DNA synthesis in human endome-
trial stromal cells. Stromal cell lines (n
15), each derived from a different human
endometrium, were cultured with or
without 10 ng/ml sol-HB-EGF in
serum-free medium, and DNA synthesis
assays were performed at passages 1–6
(A). Stromal cells were cultured with or
without 10 ng/ml sol-HB-EGF in serum-
free medium or in medium supplemented
with 5% FCS (n7; B). Crude membrane
preparations from CHO/vector and CHO/
HB-EGF were analyzed by Western blot
with antibodies to HB-EGF precursor
(C). Stromal cells cultures overlaid with
medium, fixed CHO/HB-EGF, or fixed
CHO/vector and cultured in serum-free
medium (n  6; D). DNA synthesis was
assessed by measurement of the incorpo-
ration of [3H]thymidine into the cells. In-
corporation of [3H]thymidine into cells in
the absence of HB-EGF was taken as
100% (control). Each bar represents the
mean SEM of at least four independent
experiments with each individual cell
line. *, Significant difference (P  0.05)
compared with the control.
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synthesis in stromal cells 3- to 6-fold more than in cells
cultured in medium alone, indicating that additional
membrane-associated factors also contributed to the induc-
tion of DNA synthesis in stromal cells via a juxtacrine
pathway.
HB-EGF-induces phosphorylation of EGFR, but not ErbB4
Previously, HB-EGF has been shown to induce phospho-
rylation of EGFR (9) and ErbB4 (14) in transfected cell lines
overexpressing these receptors. We therefore examined re-
ceptor phosphorylation in endometrial stromal cells exposed
to sol- and tm-HB-EGF to determine which of the receptors,
EGFR or ErbB4, mediates the activity of HB-EGF in these cells
(Fig. 4). Our data demonstrated that EGFR, but not ErbB4,
was phosphorylated in response to sol-HB-EGF (Fig. 4A).
Phosphorylation of EGFR in response to HB-EGF was con-
sistently detected in stromal cells of different passages (data
not shown). Phosphorylation of ErbB4 was not manifested
when cells were induced with sol-HB-EGF, even in medium
containing 10% serum (results not shown). Stimulation of
cells with CHO/HB-EGF cell preparations also resulted in
phosphorylation of EGFR, but not that of ErbB4 (Fig. 4B). The
presence of both EGFR and ErbB4 in the stromal cells was
demonstrated in Western blots of the cell lysates (Fig. 4C). A
major band of approximately 150 kDa corresponding to the
full-length EGFR was detected. The major band in the ErbB4
blot was approximately 100 kDa, and there were also minor
bands of higher molecular weight, but lower than the pre-
dicted full-length ErbB4 species (140 kDa).
EGFR mediates DNA synthesis in endometrial stromal cells
Having determined that EGFR is phosphorylated in re-
sponse to HB-EGF, we investigated the role of EGFR in
mediating the downstream functional effects of HB-EGF by
the use of PD153035, which selectively inhibits the protein
tyrosine kinase activity of EGFR (Fig. 5). Our data showed
that PD153035 suppressed sol-HB-EGF-induced DNA syn-
thesis in stromal cells to levels comparable to those in the
medium control.
TNF acts cooperatively with HB-EGF and the EGFR
ligands EGF, TGF, and BTC to induce DNA synthesis in
endometrial stromal cells
The increase in HB-EGF-induced DNA synthesis we ob-
served in the presence of serum (see Fig. 3B) suggested that
additional factors present in serum have an additive effect on
HB-EGF activity. We examined the possibility that TNF can
modulate HB-EGF function and that of other EGF family
ligands that bind EGFR (EGF, TGF, and BTC) in endome-
trial stromal cells (Fig. 6). TNF did not significantly induce
DNA synthesis in stromal cells, whereas EGF, TGF, and
BTC induced up to a 2-fold increase in each case. However,
simultaneous stimulation of stromal cells with TNF and
HB-EGF, EGF, TGF, or BTC in serum-free medium resulted
in a 3.5- to 4-fold increase in DNA synthesis compared with
FIG. 4. HB-EGF induces phosphoryla-
tion of EGFR, but not ErbB4. Serum-
starved endometrial stromal cells were
stimulated with either sol-HB-EGF (A)
or HB-EGF-precursor (B). Control cells
were treated with medium alone. Whole
cell lysates were prepared and immu-
noprecipitated (IP) with either anti-
EGFR or anti-ErbB4. Samples were
separated by 7.5% SDS-PAGE and sub-
jected to Western blotting (WB) with
antiphosphotyrosine antibodies (A and
B), anti-EGFR, or anti-ErbB4 antibod-
ies (C).
FIG. 5. Induction of DNA synthesis in endometrial stromal cells by
HB-EGF is mediated by EGFR. DNA synthesis in endometrial stro-
mal cells induced by sol-HB-EGF (10 ng/ml) is suppressed by
PD153035 (2 M; HB-EGF/PD). Each bar represents the mean  SEM
of four replicates in each of three independent experiments.
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the controls, more than the sum of the increase induced by
each ligand on its own (Fig. 6).
TNF increases the levels of EGFR on endometrial
stromal cells
We examined one of the possible mechanisms by which
the modulation of HB-EGF activity by TNF could be facil-
itated by assessing the expression of EGFR in endometrial
stromal cells in response to TNF by the use of quantitative
flow cytometry (Fig. 7). TNF induced increased levels of
EGFR that were detected on the membranes of the endome-
trial stromal cells relative to the controls labeled with IgG.
Discussion
There is persuasive evidence suggesting that HB-EGF and
other EGFR ligands have important functions in reproduc-
tion. The results presented here suggest a function for sol-
and tm-HB-EGF and the EGFR ligands EGF, TGF, and BTC
in the proliferation of human endometrial stromal cells. Our
experiments demonstrate that 1) tm-HB-EGF expression in
the human endometrium is spatially modulated in a cycle
stage-dependent fashion; 2) sol- and tm-HB-EGF modulate
the proliferative capacity of stromal cells; 3) the proliferative
capacity of both sol- and tm-HB-EGF is mediated via EGFR
and not ErbB4; and 4) TNF can act cooperatively with
sol-HB-EGF, EGF, TGF, and BTC to induce DNA synthesis
in stromal cells.
The expression of HB-EGF mRNA and sol-HB-EGF pro-
tein in the human endometrium has been shown previously
to increase before the implantation window (8, 21). Although
there are conflicting data on the expression of EGFR,
Srinivasan et al. (24) showed that ErbB4 is expressed at high
levels in the endometrial stroma and that it accumulates in
the glands during the secretory stage of the cycle. Here we
have demonstrated that during the proliferative stage of the
menstrual cycle tm-HB-EGF is expressed in the glands and
stroma of the basalis layer of the endometrium. With the
progression of the cycle to the secretory stage, the level of
tm-HB-EGF increases, and it can be detected on the basal
membrane of glands and on stromal cell membranes in both
the basalis and functionalis layers, suggesting a function for
tm-HB-EGF in endometrial maturation before blastocyst im-
plantation. Here we used human endometrial stromal cell
lines as a model for investigating possible functions for HB-
EGF function. We have demonstrated that these cultured
stromal cells retain the expression profile of a number of
markers and their responsiveness to a number of growth-
inducing factors, the collective data for which are not within
the scope of the present report. Pertinent to this study are our
data showing that the cultured endometrial stromal cells we
describe retain their expression of tm-HB-EGF and its re-
ceptors, EGFR and ErbB4, and their responsiveness to HB-
EGF with passaging, thus validating the use of these cell lines
as a suitable model system for investigating the function of
endometrial HB-EGF.
The preparation of the endometrium for implantation of
the embryo involves a dramatic increase in endometrial mass
FIG. 6. Cooperativity of TNF and HB-EGF and EGFR ligands, EGF,
TGF, and BTC, in the induction of DNA synthesis in endometrial
stromal cells. Stromal cells were stimulated with 10 ng/ml HB-EGF
(HB), EGF, TGF, and BTC alone () or in the presence of 10 ng/ml
TNF (f). Control cells (ctrl) were cultured with (f) or without ()
10 ng/ml TNF. Incorporation of [3H]thymidine in cells in the absence
of the exogenous factors was taken as 100% (ctrl; ). Each bar rep-
resents the mean SEM of four replicates in each of four independent
experiments with different cell lines.
FIG. 7. TNF increases levels of EGFR in endometrial stromal cells.
FACS analysis of stromal cells incubated in the absence (A) or pres-
ence (B) of 10 ng/ml TNF, labeled with mouse anti-EGFR antibodies
(f) or mouse IgG (). The graphs are representative of data obtained
from 11 independent stromal cell lines.
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that is regulated by steroid hormones. However, it is clear
that the effects of steroid hormones on endometrial cells are
mediated in part by a number of growth factors (38, 39). A
previous report demonstrated that EGF and TGF could
stimulate the proliferation of endometrial stromal cells in
culture, whereas TNF has no effect (40) and is thus in
agreement with our data, and others have reported that EGF
has no effect on stromal cell proliferation (41). Also, it has
been shown that HB-EGF levels are differentially regulated
by estradiol and progesterone in rat uterine epithelium and
stroma (42) and in the baboon (19) in vivo, indicating that it
is a good candidate for a molecular mediator of steroid action
in the endometrium. Here we show that human stromal cells
increase DNA synthesis in response to sol-HB-EGF, indicat-
ing that sol-HB-EGF may contribute to endometrial matu-
ration by promoting the proliferation of endometrial stromal
cells.
We tested the potential mitogenic activity of tm-HB-EGF
in the endometrium by the use of CHO cell lines overex-
pressing tm-HB-EGF on the cell surface. These experiments
demonstrate that CHO/HB-EGF cells can promote DNA
synthesis and suggest a function for tm-HB-EGF as a juxta-
crine growth factor in the human endometrium. Interest-
ingly, the control cell line, CHO/vector, also had a signifi-
cant effect on DNA synthesis, suggesting that additional
membrane-bound factors are involved in juxtacrine activity.
We therefore propose that HB-EGF can act as a mitogenic
factor for stromal cells in the human endometrium and that
the mitogenic activity of HB-EGF can be mediated or stim-
ulated by additional soluble or membrane-associated regu-
lators. Further investigations will elucidate the importance of
the association of tm-HB-EGF with such activity-modulating
factors, for example CD9 (43) and 31 (44), in the context of
the endometrial stromal cell membrane.
The mechanism of HB-EGF action was analyzed by ex-
amining the effect of HB-EGF on the tyrosine phosphoryla-
tion status of HB-EGF receptors, EGFR and ErbB4, both of
which are expressed in human endometrium (24, 34, 45). We
demonstrate that the addition of HB-EGF to stromal cells in
culture results in tyrosine phosphorylation of EGFR, but
ErbB4 phosphorylation was not detected, suggesting that
HB-EGF-induced proliferation in these cells is mediated via
EGFR. This was corroborated by the observation that
PD153035, a specific inhibitor of EGFR tyrosine kinase (46),
suppresses HB-EGF-induced DNA synthesis in stromal cells.
These results are in agreement with previous studies that
suggest a role for EGFR, but not ErbB4, in mediating a pro-
liferative response in transformed cell lines (14). Previous
reports indicate that ErbB4 activation is coupled to a differ-
entiation, rather than proliferation, pathway (34, 47). There-
fore, we cannot rule out the possibility that activation of
endometrial ErbB4 may be associated with differentiation or
other cellular processes in the endometrial stroma.
The full-length ErbB4 protein is 180 kDa, yet the major
band we detected in Western blots of cell lysates using anti-
ErbB4 was approximately 100 kDa. Different molecular
weight species of ErbB4 derived by differential glycosylation
and/or proteolytic cleavage are seen in other cell types (48,
49). Taking into account the predicted molecular weight of
the full-length ErbB4 (144 kDa), it can be suggested that the
vast majority of ErbB4 synthesized by endometrial stromal
cells is cleaved and is not phosphorylated by HB-EGF. This
introduces an additional mechanism by which HB-EGF func-
tion may be regulated in the human endometrium.
The onset of the menstrual stage of the cycle is thought to
be regulated by many factors, including TNF acting as an
apoptosis-inducing factor that inhibits proliferation of epi-
thelial cells and promotes endometrial shedding (28, 50, 51).
TNF is biologically active in both transmembrane and sol-
uble forms (reviewed in Ref. 52). Previously it was shown to
have a synergistic effect with fibroblast growth factor on the
proliferation of endometrial stromal cells, whereas no stim-
ulation of stromal cell proliferation was observed with TNF
alone (40). In other systems, TNF has been shown to mod-
ulate the activity of EGFR and thus regulate the function of
EGFR ligands (53–55). Here we observed that TNF has an
additive effect on the induction of DNA synthesis by sol-
HB-EGF in endometrial stromal cells. Thus, both HB-EGF
and TNF may be involved in the process of endometrial
regeneration and maturation. A cooperative effect of TNF
on other EGFR ligands, EGF, TGF, and BTC expressed in
human endometrium (24, 56), was also observed. TNF has
been shown to promote tyrosine phosphorylation and ex-
pression of EGFR in some cell lines (57, 58). We found that
TNF increases the levels of EGFR in endometrial stromal
cells. Tyrosine phosphorylation of EGFR was not observed
when stromal cells were stimulated with TNF (data not
shown). The TNF-induced increase in EGFR levels could
therefore account for the increase in the proliferative capacity
of stromal cells in response to HB-EGF, EGF, TGF, and BTC
observed in the presence of TNF.
In summary, we propose that in humans, sol- and tm-HB-
EGF have a key function in endometrial regeneration and
preparation of the endometrium for embryo implantation,
and that TNF is among the potential key factors regulating
the activities of HB-EGF and other EGFR ligands. We suggest
that endometrial HB-EGF acts as a mitogenic factor via jux-
tacrine as well as autocrine and paracrine pathways, and that
TNF acts cooperatively with HB-EGF to induce the prolif-
eration of stromal cells in the endometrium. Finally, our data
firmly support existing evidence that EGFR and ErbB4 may
have distinct functions in the human endometrium.
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